The potential value of cell therapy in wound care applications grabbed the attention of the biotech world last fall when Smith & Nephew plc, of London, picked up Fort Worth, Texas-based Healthpoint Biotherapeutics for $782 million in cash on the strength of its cell therapy product, HP802-247, in wound care.